10x Genomics said it will extend proteomics capabilities through its acquisition of Proteintech Genomics. The company characterized the purchase as strengthening its roadmap for integrated single-cell and spatial multiomics, including assays designed to work seamlessly on 10x platforms. Proteintech Genomics’ antibody panel and assay workflow support transcriptomic measurement alongside protein detection, addressing demand for more unified cellular identity and state profiling. 10x said it expects the combined portfolios will enable customers to deploy multiomic experiments at scale and with quality and pricing advantages. For platform providers, consolidation around multiomics tools is increasingly about compatibility—assay harmonization, faster onboarding for existing customers, and reduced experimental variability. The deal reinforces a strategic shift: proteomics is becoming a core feature expectation rather than an optional add-on in many single-cell workflows.